<unk>  is approved for and mainly used in the following indications: * Metastatic prostate cancer (mPC) in men in combination with a gonadotropin-releasing hormone (GnRH) analogue or surgical castration at 50 mg/day * Locally advanced prostate cancer (LAPC) in men as a monotherapy at 150 mg/day (not approved for this use in the United States) In Japan,<unk>  is uniquely used at a dosage of 80 mg/day both in combination with castration and as a monotherapy in the treatment of prostate cancer.<unk>  is also employed for the following off-label (non-approved) indications: * To reduce the effects of the testosterone flare at the initiation of agonist therapy in men * Androgen-dependent skin and hair conditions such as acne, seborrhea, excessive hair growth, and scalp hair loss in women as well as high testosterone levels due to polycystic ovary syndrome (PCOS) in women, at 25 to 50 mg/day generally in combination with a birth control pill * Feminizing hormone therapy for transgender women in combination with an estrogen usually at 50 mg/day * Peripheral precocious puberty in boys at 12.5 to 100 mg/day in combination with an aromatase inhibitor like anastrozole, especially for familial male-limited precocious puberty (testotoxicosis) * Overly long-lasting erections in men at 50 mg per week to 50 mg every other day The medication has been suggested for but has uncertain effectiveness in the following indication: * Hypersexuality and paraphilias, particularly in combination with chemical castration For more information on these uses, see the medical uses of<unk>  article. Available forms<unk>  is available for the treatment of prostate cancer in most developed countries, including over 80 countries worldwide. It is available in 50 mg, 80 mg (in Japan), and 150 mg tablets for oral administration. The drug is registered for use as a 150 mg/day monotherapy for the treatment of in at least 55 countries, with the being a notable exception where it is registered only for use at a dosage of 50 mg/day in combination with castration. No other formulations or routes of administration are available or used. All formulations of<unk>  are specifically indicated for the treatment of prostate cancer alone or in combination with surgical or medication castration. A combined formulation of<unk>  and the agonist goserelin in which goserelin is provided as a subcutaneous implant for injection and<unk>  is included as 50 mg tablets for oral ingestion is marketed in Australia and New Zealand under the brand name ZolaCos CP (Zoladex–Cosudex Combination Pack).
Bicalutamide
Darolutamide
Topilutamide
Apalutamide
Nilutamide
Acetothiolutamide
Flutamide
Enzalutamide